EMJ Dermatology 13 [Supplement 3] . 2025

In this issue

In this interview, two dermatology experts from Germany share their treatment experiences of using lebrikizumab to treat patients with moderate-to-severe atopic dermatitis (AD) in daily clinical practice. Read now to find out how lebrikizumab’s real-world efficacy and safety aligns with findings from the pivotal ADvocate clinical trials, and where this biologic fits within the overall AD treatment landscape.